Citius Oncology (CTOR) Competitors $0.92 +0.04 (+3.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.91 -0.02 (-1.62%) As of 05/2/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. GOSS, DMAC, IVA, MDWD, ELDN, CRDF, VYGR, ALMS, FULC, and BTMDShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Gossamer Bio (GOSS), DiaMedica Therapeutics (DMAC), Inventiva (IVA), MediWound (MDWD), Eledon Pharmaceuticals (ELDN), Cardiff Oncology (CRDF), Voyager Therapeutics (VYGR), Alumis (ALMS), Fulcrum Therapeutics (FULC), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Gossamer Bio DiaMedica Therapeutics Inventiva MediWound Eledon Pharmaceuticals Cardiff Oncology Voyager Therapeutics Alumis Fulcrum Therapeutics biote Gossamer Bio (NASDAQ:GOSS) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Do institutionals and insiders believe in GOSS or CTOR? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate GOSS or CTOR? Gossamer Bio presently has a consensus price target of $7.50, indicating a potential upside of 535.59%. Citius Oncology has a consensus price target of $3.00, indicating a potential upside of 224.32%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, GOSS or CTOR? Citius Oncology has lower revenue, but higher earnings than Gossamer Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M2.34-$179.82M-$0.26-4.54Citius OncologyN/AN/A-$21.15MN/AN/A Which has more volatility and risk, GOSS or CTOR? Gossamer Bio has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Does the MarketBeat Community prefer GOSS or CTOR? Gossamer Bio received 154 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 66.81% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15566.81% Underperform Votes7733.19% Citius OncologyOutperform Votes1100.00% Underperform VotesNo Votes Is GOSS or CTOR more profitable? Citius Oncology's return on equity of -43.67% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Citius Oncology N/A -43.67%-9.74% Does the media refer more to GOSS or CTOR? In the previous week, Gossamer Bio had 3 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Gossamer Bio and 0 mentions for Citius Oncology. Gossamer Bio's average media sentiment score of 0.87 beat Citius Oncology's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Overall Sentiment Gossamer Bio Positive Citius Oncology Neutral SummaryGossamer Bio beats Citius Oncology on 9 of the 13 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.19M$6.85B$5.55B$8.03BDividend YieldN/A2.96%5.09%4.23%P/E RatioN/A7.4722.7118.87Price / SalesN/A258.42405.55106.92Price / CashN/A65.8538.1834.62Price / Book-4.206.566.794.34Net Income-$21.15M$143.41M$3.22B$248.06M7 Day Performance26.89%3.37%3.34%3.21%1 Month Performance30.83%10.31%6.90%8.30%1 Year PerformanceN/A-3.67%16.21%5.06% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$0.93+3.9%$3.00+224.3%N/A$66.19MN/A0.00N/AUpcoming EarningsNews CoverageGap UpGOSSGossamer Bio4.0516 of 5 stars$0.88-8.5%$7.50+755.8%+53.0%$199.14M$114.70M-2.74180Upcoming EarningsNews CoverageDMACDiaMedica Therapeutics1.6138 of 5 stars$4.64+14.9%$8.00+72.4%+60.8%$198.85MN/A-8.2920Upcoming EarningsNews CoverageHigh Trading VolumeIVAInventiva1.7854 of 5 stars$3.78-2.7%$10.40+174.8%+5.6%$198.57M$9.20M0.00100MDWDMediWound1.4506 of 5 stars$18.29+1.2%$31.33+71.3%-8.4%$197.68M$20.22M-6.3180Analyst ForecastNews CoverageELDNEledon Pharmaceuticals2.2446 of 5 stars$3.28+1.2%$12.50+281.1%+43.9%$196.41MN/A-1.6310Upcoming EarningsShort Interest ↑News CoverageCRDFCardiff Oncology1.4583 of 5 stars$2.95+2.4%$11.67+295.5%-37.1%$196.25M$683,000.00-3.1420News CoverageVYGRVoyager Therapeutics4.5935 of 5 stars$3.53+1.7%$13.97+295.6%-57.3%$195.26M$80.00M4.97100Positive NewsALMSAlumis2.4552 of 5 stars$4.12-3.7%$25.86+527.6%N/A$194.56MN/A0.00N/AAnalyst ForecastFULCFulcrum Therapeutics1.9406 of 5 stars$3.57+1.1%$8.63+141.6%-26.5%$192.71M$80M-11.52100Earnings ReportNews CoverageBTMDbiote3.8259 of 5 stars$3.47+1.2%$8.00+130.5%-39.8%$189.84M$197.19M13.35194Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Gossamer Bio Competitors DiaMedica Therapeutics Competitors Inventiva Competitors MediWound Competitors Eledon Pharmaceuticals Competitors Cardiff Oncology Competitors Voyager Therapeutics Competitors Alumis Competitors Fulcrum Therapeutics Competitors biote Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
